UXCONTRACTNETWORK

UX Contract › Grants › RFA-AG-28-009

FORECAST · COOPERATIVE AGREEMENT

Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

National Institutes of Health · Health

Forecast. The agency expects to post this grant around Mar 10, 2027 (fiscal year 2028). Dates and amounts are estimates until the notice posts.
Expected deadline
Not stated
Who can apply
Others
Award range
Not stated
Expected awards
Not stated
Total program funding
Not stated
Your own money required
No cost sharing or matching required
Opportunity number
RFA-AG-28-009
Posted
Aug 13, 2026
Assistance listing
93.866

More on who can apply

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;

What it funds

The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that propose pre-clinical and early-stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that aim to prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms.Through the NOFO, NIA is continuing the Alzheimer's Drug-Development Program (ADDP) with the aim of catalyzing drug development for AD. The ADDP is designed to provide funding support to academic and biotech researchers for preclinical drug development activities that can be conducted in their own laboratories or conducted in collaboration with contract research organizations that specialize in preclinical drug development activities. By supporting the most challenging and costly steps of drug development and seamlessly connecting preclinical drug development and first-in-human testing for drug candidates, the ADDP program seeks to: Continue to expand the number of investigational new drug candidates for a portfolio of emerging therapeutic targets; Continue to expand the therapeutic pipeline for AD with drug candidates targeting multiple underlying disease mechanisms that can be used as mono-therapy or as part of combination therapy; and Enable a precision medicine approach to AD drug development. The NOFO will utilize the U01 activity code. Applications are not being solicited at this time. This notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

Open the official notice on Grants.gov ↗

What to do next

  1. This is a forecast: the agency expects to post the full notice later. Open it on Grants.gov and subscribe there to be told when it posts.
  2. Get your SAM.gov registration ("all awards") and Grants.gov account active now; both take time.
  3. Use the forecast's award range and eligibility to decide whether to prepare.
  4. Watch for the notice; the dates here are estimates and can change.

New to this? Applying for a federal grant, step by step · Register to apply · How to read the notice · Write the narrative · Build the budget · Agency contact: NIA-NOFO-Scientific@nih.gov

From Grants.gov's official daily extract of Oct 25, 2026. The notice on Grants.gov and its attachments are what count. UX Contract is independent and not a government website.

Just listed by agency

Live feed →

More health grants accepting applications

Track the auctions and bids you're watching in UX Console

See plans →

Saved searches, closing and deadline alerts, and your won auctions with the real costs, in one workspace. From $10 a month. Every site in the UX Network stays free.